摘要
目的探讨非瓣膜心房颤动(NVAF)患者血浆分子标志物凝血酶-抗凝血酶Ⅲ(TAT)、vWF浓度变化及其价值。方法研究期间,外周动脉明确存在血栓栓塞并发症的NVAF患者8例为栓塞组;排除外周动脉血栓栓塞并发症的NVAF患者24例为房颤组,对照组25例为无房颤组。各组均分别采用酶联免疫双抗体夹心法(ELISA)测定血浆TAT、vWF活性,对其结果进行对比分析。结果NVAF患者无论是否存在血栓栓塞并发症,其TAT及vWF含量均明显高于无房颤组(P<0.05)。栓塞组患者TAT、vWF水平明显高于房颤组(P均<0.05)。结论房颤可引起凝血系统的激活及内皮系统的损害,检测房颤患者血浆中TAT、vWF可能成为评估房颤患者血栓栓塞危险性的一种有价值的方法。
Objective To study the alteration of plasma molecular marker thrombin-antithrombin Ⅲ（TAT） and vWF levels and the value of these markers in evaluating embolic risk in patients with atrial fibrillation（AF）.Methods Plasma TAT,vWF were respectively determined in patients with AF and 25 volunteers with sinus rhythm by enzyme linked immunosorbent assay （ELISA）.The thrombembolism group（n=8） included 8 patients who suffered from the complications of peripheral embolism.The AF group included 24 patients without thromboembolism history.The non-AF group included 25 patients with sinus rhythm.Results Compared with the non-AF group,the levels of TAT,vWF in patients with AF increased significantly（P〈0.05）.There were also significantly differences in the levels of TAT and vWF between thrombembolism group and AF group.Conclusion AF can result in activation of coagulation system and damage of endothelial.To detect plasma TAT and vWF levels may become a new means in evaluating embolic risk in AF patients.
出处
《临床医学》
CAS
2007年第9期82-83,共2页
Clinical Medicine
